Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY I: Actoxumab and Bezlotoxumab for CDI
NCT01241552Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2011
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of bezlotoxumab, actoxumab in Clostridium difficile infection (CDI), sponsored by Merck & Co.. Started Oct 2011; status: completed.
02
Drugs
bezlotoxumabactoxumab
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01241552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241552.